Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

June 27, 2022

From Virpax Pharmaceuticals

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2022 ↗

June 09, 2022

Upgrades

Via Benzinga

Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

May 19, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19 ↗

March 15, 2022

Virpax Pharmaceuticals Inc (NASDAQ: VRPX)

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 17, 2022

Gainers

Via Benzinga

Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments

May 16, 2022

From Virpax® Pharmaceuticals, Inc.

Via Business Wire

24 Stocks Moving in Friday's Pre-Market Session ↗

May 06, 2022

Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend...

Via Benzinga

Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research

May 05, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

92 Biggest Movers From Friday ↗

May 09, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the...

Via Benzinga

55 Stocks Moving In Friday's Mid-Day Session ↗

May 06, 2022

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.

Via Benzinga

Virpax Successfully Completes Initial Preclinical Studies for VRP324

April 26, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

April 29, 2022

On Friday, 213 companies hit new 52-week lows.

Via Benzinga

Virpax Pharmaceuticals Reports 2021 Year-End Results

March 31, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™

March 22, 2022

From Virpax® Pharmaceuticals, Inc.

Via Business Wire

Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)

March 22, 2022

LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its...

From Nanomerics Ltd

Via AccessWire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 18, 2022

Gainers Sunshine Biopharma (NASDAQ:SBFM) stock increased by 15.5% to $3.5 during Friday's pre-market session. The company's market cap stands at $15.6 million....

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 15, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement

March 15, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 24, 2022

Gainers Unicycive Therapeutics (NASDAQ:UNCY

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 22, 2022

Gainers Revelation Biosciences (NASDAQ:REVB

Via Benzinga

News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19

February 15, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

February 10, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee

January 21, 2022

From Altasciences and Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

January 18, 2022

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 05, 2022

Gainers SomaLogic (NASDAQ:SLGC) shares mo...

Via Benzinga

Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

January 04, 2022

From Virpax® Pharmaceuticals, Inc.

Via Business Wire

Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

December 28, 2021

From Virpax Pharmaceuticals, Inc.

Via Business Wire

Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee

December 20, 2021

From Virpax Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.